The stock of AstraZeneca plc (ADR) (NYSE:AZN) is a huge mover today! About 7.66 million shares traded hands or 28.96% up from the average. AstraZeneca plc (ADR) (NYSE:AZN) has declined 4.85% since April 11, 2016 and is downtrending. It has underperformed by 10.99% the S&P500.
The move comes after 5 months positive chart setup for the $67.28 billion company. It was reported on Nov, 11 by Barchart.com. We have $42.55 PT which if reached, will make NYSE:AZN worth $34.31B more.
AstraZeneca plc (ADR) (NYSE:AZN) Ratings Coverage
Out of 17 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 11 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 65% are positive. AstraZeneca plc (ADR) has been the topic of 20 analyst reports since July 31, 2015 according to StockzIntelligence Inc. HBSC downgraded the shares of AZN in a report on Monday, February 8 to “Hold” rating. The rating was upgraded by Bryan Garnier & Cie to “Buy” on Friday, September 18. The firm has “Overweight” rating by Piperjaffray given on Friday, September 23. The stock of AstraZeneca plc (ADR) (NYSE:AZN) earned “Underperform” rating by Credit Suisse on Tuesday, October 20. The rating was upgraded by Oddo & Cie to “Top Pick” on Tuesday, January 26. The rating was initiated by Cantor Fitzgerald on Friday, February 26 with “Buy”. The firm has “Buy” rating by Argus Research given on Monday, August 29. Nordea downgraded the shares of AZN in a report on Monday, November 2 to “Hold” rating. On Friday, July 31 the stock rating was upgraded by Swedbank to “Buy”. Leerink Swann maintained it with “Market Perform” rating and $34 target price in Monday, May 2 report.
According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”
AZN Company Profile
AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a biopharmaceutical company. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Firm has its activities in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.